[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemoradiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemoradiotherapy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,51,75,99,130,168,196,220,253,280,303,326,355,383,406,440,464,485,508,529,547,568,590,609,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100599962","phase-2-a-study-of-ql1706-combined-with-chemotherapy-induction-on-sequential-immunotherapy-consolidation-in-patients-with-limited-stage-small-cell-lung-cancer-after-chemoradiotherapy-100599962",false,"NCT07091305","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial","Inclusion Criteria:\n\n1. The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.\n2. Pathologically confirmed LS-SCLC\n3. Investigator confirmation of at least one measurable lesion, as defined by RECIST v1.1\n4. ECOG performance status of 0 or 1\n5. Forced expiratory volume in one second (FEV₁) \\> 1.0 L\n6. No clinically significant interstitial lung disease on baseline CT or PET\u002FCT.\n7. Adequate organ and bone-marrow function (all tests performed within 7 days prior to first dose; no transfusions, growth factors, albumin, or other corrective therapies within 14 days):Hemoglobin ≥ 90 g\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 90 × 10⁹\u002FL,Serum creatinine ≤ 1.5 × ULN, TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN, Albumin (ALB) ≥ 25 g\u002FL,INR ≤ 1.5 × ULN, PT and APTT ≤ 1.5 × ULN (subjects on prophylactic anticoagulation must have values within a safe therapeutic range, per investigator)\n8. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use reliable contraception from screening until 3 months after the last dose; male subjects must agree to use effective contraception or have undergone surgical sterilization for the same period.\n9. No prior systemic anti-tumor therapy before enrollment.\n10. Estimated life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to QL1706 or any of its excipients\n2. Histologically confirmed non-small cell lung cancer (NSCLC) or mixed tumor containing an NSCLC component.\n3. History of another primary malignancy or previous allogeneic organ transplantation.\n4. Surgery (other than diagnostic biopsy) within 4 weeks before first dose of study drug.\n5. Active substance abuse (e.g., illicit drug use), chronic alcoholism, AIDS, or known HIV infection.\n6. Active autoimmune disease, or history of autoimmune disease likely to recur. Systemic corticosteroid therapy equivalent to \\>10 mg\u002Fday prednisone (or other immunosuppressive therapies) within 14 days before first dose.\n7. Prior therapy with any antibody or agent targeting T-cell co-regulatory proteins (e.g., PD-1, PD-L1, CTLA-4, TIM-3, LAG-3).\n8. Interstitial lung disease (ILD), or history of ILD requiring steroid therapy. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonia on screening chest CT.\n9. Live vaccine administration within 28 days prior to first study drug dose. Any condition or comorbidity contraindicating chemo- or radiotherapy (e.g., active infection, myocardial infarction within 6 months, symptomatic heart disease including unstable angina, congestive heart failure, uncontrolled arrhythmia, ongoing immunosuppressive therapy).\n10. Pregnant or breastfeeding women; women of childbearing potential or men unwilling to use adequate contraception.\n11. Known hereditary bleeding diathesis or coagulation disorder.\n12. Prior malignancy, except adequately treated non-melanoma skin cancer, or in situ carcinoma (e.g., breast, oral, cervical) with expected survival \\>3 years.\n13. Any other medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, could interfere with trial participation or interpretation of results.","ALL","18 Years","75 Years",{"count":21,"type":22},28,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The study is being conducted to evaluation of the Efficacy and Safety of QL1706 Combined with Chemotherapy Induction in Sequential Immunotherapy Consolidation After Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer(LS-SCLC), and Exploration of the Correlation Between Biomarkers (PD-L1, TMB, ctDNA, etc.) Related to QL1706 Treatment and Treatment Efficacy and Prognosis.\n\nQL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.",[28,29,30,31],"Limited-stage Small Cell Lung Cancer (LS-SCLC)","Chemoradiotherapy","Induction Therapy","Consolidation Immunotherapy",[33,34,35,36,37],"Limited-stage small cell lung cancer","QL1706","chemoradiotherapy","induction therapy","consolidation immunotherapy","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2025-10-23",{"date":46,"type":22},"2028-08-01",{"name":48,"class":49},"Shanghai Chest Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100624022","multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant-treatment-100624022","NCT07404228","Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment","RESTAGE","Inclusion Criteria for the preclinical phase :\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Have completed neoadjuvant chemoradiotherapy;\n* Be a candidate for surgical treatment with total mesorectal excision;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.\n\nInclusion criteria for the clinical phase:\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Require neoadjuvant chemoradiotherapy or have completed neoadjuvant chemoradiotherapy;\n* Requires either surgical treatment or a non-surgical strategy (\"Watch-and-Wait\") after neoadjuvant chemoradiotherapy;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.",{"count":59,"type":22},115,"OBSERVATIONAL","Rectal cancer presents a significant global health challenge. Despite improvements in clinical outcomes, significant disparities persist across Europe. These differences are explained not only by the heterogeneity of risk factors and screening strategies, but also by variations in diagnostic and therapeutic approaches, which are highly dependent on medical imaging.\n\nStandard treatment for locally advanced rectal cancer based on staging MRI is neoadjuvant treatment (NAT), for tumour downsizing and downstaging, followed by total mesorectal excision. In a significant proportion of cases, radical surgery leads to substantial long-term complications like sexual and urinary dysfunction, fecal incontinence, and impairment in daily activities. Given that up to 42% of patients show complete tumor regression at pathology (i.e. pathological complete response pCR), to avoid unnecessary radical surgery, non-operative management has become an attractive alternative when there are no signs of viable tumour after NAT (i.e. clinical complete response cCR). Such patients are candidates for Watch-and-Wait (W\\&W), an established active surveillance policy in specialized centers worldwide relying on clinical examination, endoscopy and MRI.\n\nOn the other hand, W\\&W carries a risk of local regrowth (persistence of microscopic residual disease despite apparent cCR). Even in expert hands, assessment of tumor response is not perfect and local regrowth based on current selection methods occurs in \\~30% of cases. Although deferred surgery is a successful treatment with no apparent negative impact on local disease control, an increased rate of distant metastases has been recently reported.\n\nTherefore, there is a critical unmet clinical need to detect complete responses after NAT and avoid unnecessary surgery with its associated morbidity and quality of life impairment risks, while also improving sensitivity for residual microscopic disease that will result in local regrowth and associated reduced disease-free survival.\n\nRectal cancer poses a burden not only on healthcare systems, but also on patient well-being. Patients frequently suffer from feelings of isolation and helplessness when faced with unpredicted disease-related situations, given the common difficulties to access high quality information and communicate with attending physicians. As such, there is a clear need to unburden healthcare facilities from unnecessary hospital visits, while improving patient outcomes, engagement, support and care.",[63,29,64],"Rectal Cancer","Mri","NOT_YET_RECRUITING","2026-06-02",{"date":68,"type":42},"2026-06-04",{"date":70,"type":22},"2026-08",{"date":72,"type":22},"2029-11",{"name":74,"class":49},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100637461","phase-2-shr-1701-for-induction-and-consolidation-therapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-100637461","NCT07619911","SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer","SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Randomized, Phase II Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Baseline ECOG performance status 0-1.\n* Histologically or cytologically confirmed unresectable stage III NSCLC\n* Life expectancy ≥3 months\n* No prior anti-tumor therapy\n* No known EGFR\u002FALK\u002FROS1 sensitive mutations\n* At least one measurable lesion according to RECIST v1.1\n* Adequate organ function\n* Signed informed consent\n\nExclusion Criteria:\n\n* Mixed small-cell and non-small-cell lung cancer histology\n* Known EGFR\u002FALK\u002FROS1 mutations\n* Prior systemic anti-cancer therapy within 4 weeks\n* Active autoimmune disease requiring systemic treatment\n* Active infection including uncontrolled HBV, HCV or HIV infection\n* Significant cardiovascular disease\n* Uncontrolled hypertension\n* Pregnancy or breastfeeding\n* Participation in another interventional clinical trial",{"count":83,"type":22},84,[25],"This randomized phase II exploratory clinical study aims to evaluate the efficacy and safety of SHR-1701 in patients with unresectable stage III non-small cell lung cancer (NSCLC). A total of 84 eligible patients will be randomized 1:1 into an induction immunotherapy group or a consolidation immunotherapy group. Group A will receive SHR-1701 combined with platinum-based chemotherapy as induction therapy followed by concurrent chemoradiotherapy (cCRT) and subsequent SHR-1701 consolidation therapy, while Group B will receive standard cCRT followed by SHR-1701 consolidation therapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety outcomes.",[87,88,29],"NSCLC Stage III","SHR-1701",[90,88,35],"NSCLC","2026-05-27",{"date":66,"type":42},{"date":94,"type":22},"2026-07",{"date":96,"type":22},"2030-12",{"name":98,"class":49},"Fudan University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":60,"phases":4,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":50},"100532920","nutritional-status-and-clinical-outcomes-in-patients-with-common-malignanciesncom-100532920","NCT06219083","Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)","Study of Nutritional Status and Clinical Outcomes in Patients With Common Malignancies","NCOM","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Pathologically diagnosed with malignant tumors\n* Scheduled to undergo radiotherapy and\u002For chemotherapy\n* Clear consciousness, no communication barriers\n* Willing to undergo follow-up, not in a near-death condition\n\nExclusion Criteria:\n\n* Patients without a pathological diagnosis of malignant tumors\n* Patients with AIDS\n* Patients with mental or cognitive disorders\n* Patients who have undergone organ transplantation\n* Patients with a life expectancy less than 12 months\n* Pregnant women\n* Patients currently participating in other clinical intervention studies",{"count":108,"type":22},1538,"5 Years","This multicenter, prospective cohort study investigates the long-term impact of nutritional status on clinical outcomes in cancer patients undergoing treatment in Shaanxi Province, China. It evaluates how malnutrition, dietary patterns, and nutritional interventions affect treatment tolerance, quality of life, and survival. The study tracks dynamic changes in nutritional health and related indicators throughout various stages of chemoradiotherapy, aiming to inform evidence-based strategies for precision nutrition in oncology care.",[112,29,113,114,115],"Cancer","Nutrition, Healthy","Oncology","Clinical Outcomes",[29,117,118,119,120],"Nutritional Status in Cancer Patients","Clinical Outcomes of Cancer Treatment","Cancer Patient Nutrition","Shaanxi Province Cancer Study","2026-05-10",{"date":123,"type":42},"2026-05-12",{"date":125,"type":42},"2020-11-12",{"date":127,"type":22},"2031-12-01",{"name":129,"class":49},"Xiaoqin Luo",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":141,"conditions":142,"keywords":152,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":50},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":138,"type":22},400,[25,140],"PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[63,143,144,145,146,147,148,149,29,150,151],"Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Chemotherapy","Organ Preservation","Radiotherapy Side Effect","Chemotherapy Side Effects","Low Anterior Resection Syndrome","Quality of Life",[153,143,154,145,146,29,147,148,155,156,157,158,150],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","2026-05-06",{"date":161,"type":42},"2026-05-11",{"date":163,"type":42},"2025-01-06",{"date":165,"type":22},"2029-12-27",{"name":167,"class":49},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":50},"100606610","phase-3-consolidation-of-toripalimab-and-capecitabine-after-chemoradiotherapy-in-escc-100606610","NCT07177794","Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC","Toripalimab Combined With Capecitabine as Maintenance Therapy After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized Controlled, Phase III Trial (EC-CRT-008)","EC-CRT-008","Inclusion Criteria:\n\n1. Histologically confirmed squamous cell carcinoma of the esophagus;\n2. Locally advanced esophageal cancer classified as stage I-IVA (inoperable or patient declined surgery) or stage IVB thoracic esophageal cancer with supraclavicular lymph node metastasis only (AJCC 8th edition) prior to treatment;\n3. Completion of definitive concurrent chemoradiotherapy without disease progression; radiotherapy dose of 50-50.4 Gy using conventional fractionation and IMRT technique; concurrent platinum- or taxane-based doublet chemotherapy during radiotherapy; ≤4 cycles of induction chemotherapy allowed prior to radiotherapy; PD-1\u002FPD-L1 antibody therapy permitted during induction chemotherapy and radiotherapy; no adjuvant therapy received;\n4. Enrollment window: within 1-42 days after completion of chemoradiotherapy;\n5. Age 18-75 years;\n6. Estimated life expectancy \\>6 months;\n7. Eastern Cooperative Oncology Group performance status ≤ 2;\n8. The function of important organs meets the following requirements: a. white blood cell count (WBC) ≥3.5×109\u002FL, absolute neutrophil count (ANC) ≥1.5×109\u002FL; b. platelets ≥75×109\u002FL; c. hemoglobin ≥9g\u002FdL; d. serum albumin ≥2.8g\u002FdL; e. total bilirubin ≤1.5×ULN, ALT, AST and\u002For AKP ≤2.5×ULN; f. serum creatinine ≤1.5×ULN or creatinine clearance rate \\>60 mL\u002Fmin;\n9. Ability to understand the trial details and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Patients who have received antitumor therapy (including adjuvant chemotherapy, surgery, immunotherapy, targeted therapy, etc.) after completion of chemoradiotherapy;\n2. Stage IVb patients with metastasis to solid organs (e.g., liver, bone, lung, brain, adrenal gland, peritoneum, etc.) at initial diagnosis;\n3. Known or suspected allergy to the investigational drug(s) or any agent related to the trial regimen;\n4. Presence of esophageal fistula and\u002For esophageal hemorrhage prior to enrollment;\n5. Disease progression after chemoradiotherapy;\n6. ≥Grade 2 radiation pneumonitis prior to enrollment;\n7. History of ≥ Grade 3 immune-related adverse events prior to enrollment;\n8. Prior treatment with targeted drugs;\n9. History of other malignant tumors besides esophageal cancer, except for non-melanoma skin cancer, carcinoma in situ of the cervix, papillary thyroid carcinoma, or cured early-stage prostate cancer;\n10. Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, hematopoietic system diseases, cachexia, or other conditions that make them unfit for chemotherapy;\n11. Female patients who are pregnant or breastfeeding;\n12. Inability to provide informed consent due to psychological, familial, social, or other factors;\n13. Presence of CTC grade ≥2 peripheral neuropathy;\n14. Patients with a history of diabetes for more than 10 years and poorly controlled blood glucose levels;\n15. History of autoimmune disease or autoimmune disorders (e.g., colitis, systemic lupus erythematosus, rheumatoid arthritis, uveitis, hypophysitis, hyperthyroidism; not limited to these diseases or syndromes), immunodeficiency history, including HIV positivity, or other acquired\u002Fcongenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation;\n16. History of interstitial lung disease or non-infectious pneumonia;\n17. Active hepatitis B (HBV DNA ≥2000 IU\u002FmL or 10⁴ copies\u002FmL) or hepatitis C (HCV antibody positive with HCV-RNA above the lower limit of detection);\n18. Any unstable condition that may jeopardize patient safety or compliance.",{"count":177,"type":22},242,[140],"Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effective consolidation treatment after CRT, resulting in a high recurrence rate. Our previous prospective phase II trial (EC-CRT-001) demonstrated that the addition of toripalimab to definitive CRT improved the complete response rate in patients with locally advanced esophageal squamous cell carcinoma (ESCC), showing potential for enhanced long-term survival with a manageable safety profile. Nevertheless, the risk of recurrence requires further reduction. Metronomic capecitabine chemotherapy can modulate the tumor immune microenvironment and may synergize with PD-1 antibodies to enhance antitumor efficacy, potentially further prolonging survival in ESCC. Based on current research advances and our preliminary findings, this randomized, controlled, multicenter, phase III clinical trial aims to evaluate the efficacy and safety of toripalimab combined with capecitabine as maintenance therapy for patients with locally advanced ESCC who have not progressed after definitive CRT.",[181,29],"Esophageal Cancer",[183,184,185,186],"Esophageal squamous cell carcinoma","definitive chemoradiotherapy","maintenance therapy","Toripalimab","2026-04-19",{"date":189,"type":42},"2026-04-21",{"date":191,"type":42},"2025-09-10",{"date":193,"type":22},"2030-05-31",{"name":195,"class":49},"Sun Yat-sen University",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":50},"100571395","phase-2-concurrent-chemoradiotherapy-combined-with-toripalimab-and-surufatinib-in-the-treatment-of-limited-stage-small-cell-lung-cancer-100571395","NCT06719700","Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","A Prospective Phase II Study of Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Informed Consent: An informed consent form, signed and dated, must be provided before any steps in the study are performed.\n* Age: Males or females aged 18 to 75 years.\n* Diagnosis: Histologically or cytologically confirmed small cell lung cancer (SCLC).\n* Stage: Stage I-III (AJCC\u002FUICC 8th edition TNM staging), where all lesions can be included in a single radical radiotherapy plan (i.e., limited-stage disease). Stage I-II must be inoperable.\n* Life Expectancy: ≥12 weeks.\n* Performance Status (PS): WHO PS score of 0 or 1.\n* Postmenopausal women or those with a negative urine or serum pregnancy test (HCG sensitivity ≥25 IU\u002FL or equivalent) within 7 days before starting study treatment.\n* Female participants must not be breastfeeding.\n* Women of childbearing potential (WOCBP) must agree to use contraception during study treatment and for 3 months after the last dose of study drug (i.e., 30 days for an ovulation cycle plus approximately 5 half-lives of the investigational drug).\n* Male participants engaging in sexual activity with WOCBP must agree to use contraception during study treatment and for 5 months after the last dose of study drug (i.e., 90 days for sperm regeneration cycle plus approximately 5 half-lives of the investigational drug).\n* Males with azoospermia do not need to follow contraception requirements.\n* WOCBP who are not sexually active do not need to follow contraception requirements but must still undergo pregnancy testing as outlined.\n* Organ and Bone Marrow Function:\n\nPulmonary Function: FEV1 ≥800 mL. Absolute neutrophil count ≥1.5 × 10⁹\u002FL. Platelet count ≥100 × 10⁹\u002FL. Hemoglobin ≥9.0 g\u002FdL. Renal Function: Calculated creatinine clearance ≥50 mL\u002Fmin using the Cockcroft-Gault formula.\n\nSerum bilirubin ≤1.5 × upper limit of normal (ULN). AST and ALT ≤2.5 × ULN.\n\nExclusion Criteria:\n\n* Participation in Another Clinical Trial: Simultaneous participation in another clinical trial, unless it is an observational (non-interventional) study.\n* Mixed Histology: Histological subtype of mixed small cell and non-small cell lung cancer (SCLC).\n* Extensive-Stage SCLC: Diagnosis of extensive-stage SCLC.\n* Malignant Effusions: Pathologically confirmed malignant pleural effusion or pericardial effusion.\n* Hemoptysis: Central cavitary SCLC with hemoptysis (hemoptysis volume \\>50 ml\u002Fday).\n* Immunosuppressive Treatment: Use of immunosuppressive drugs within 28 days prior to the first dose of toripalimab. Physiological doses of intranasal corticosteroids and systemic corticosteroids ≤10 mg daily of prednisone (or equivalent) are exceptions. Steroids used to manage chemoradiotherapy-related toxicities are allowed.\n* Previous Anti-PD-1\u002FPD-L1 Therapy: Prior use of any anti-PD-1 or anti-PD-L1 antibodies.\n* Major Surgery: Underwent major surgery (excluding vascular access) within 4 weeks before study entry.\n* Autoimmune Disease History: History of autoimmune diseases within the last 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis.\n* Primary Immunodeficiency: History of primary immunodeficiency.\n* Organ Transplant History: History of organ transplantation requiring immunosuppressive treatment.\n* QT Interval Prolongation: QTc interval (corrected by Bazett's formula) \\>470 ms, calculated from three ECG measurements.\n* Uncontrolled Comorbidities: Uncontrolled comorbid conditions, including but not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, arrhythmias, active peptic ulcer disease or gastritis, active bleeding disorders, chronic hepatitis C, HIV infection, HBsAg-positive patients with DNA \\>500 IU\u002Fml, or any psychiatric or social conditions that may interfere with study requirements or the patient's ability to provide informed consent.\n* Tuberculosis History: Known history of tuberculosis.\n* Live Vaccination: Received a live attenuated vaccine within 30 days prior to study initiation.\n* Previous Primary Malignancy: History of another primary malignancy within 5 years prior to study entry, except for adequately treated basal or squamous cell carcinoma of the skin, in situ cervical cancer, ductal carcinoma in situ of the breast, or localized prostate cancer.\n* Pregnancy and Breastfeeding: Pregnant or breastfeeding women, or men and women of reproductive potential who are not using effective contraception.\n* Interference with Study Assessment: Any condition that may interfere with the evaluation of toripalimab's efficacy or safety.\n* Investigator's Discretion: Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.",{"count":204,"type":22},47,[25],"Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.",[186,208,29,28],"Surufatinib",[186,208,29,210,211],"Limited-stage small cell lung cancer (LS-SCLC)","Immunotherapy consolidation","2026-02-28",{"date":214,"type":42},"2026-03-03",{"date":216,"type":42},"2024-11-30",{"date":218,"type":22},"2028-11-29",{"name":195,"class":49},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":228,"minAge":4,"maxAge":4,"enrollmentInfo":229,"targetDuration":231,"studyType":60,"phases":4,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":252},"100615312","compliance-to-cervical-cancer-chemoradiation-guidelines-a-multicentric-implementation-audit-and-resource-assessment-initiative-of-national-cancer-grid-of-india-100615312","NCT07290972","Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","NCG-Compliance","The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.\n\nFurthermore any cases referred to the institution for brachytherapy alone will also be included.","FEMALE",{"count":230,"type":22},618,"3 Years","This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+\u002F- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and\u002For concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.\n\nAs a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.\n\nEach of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.\n\nThose centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and \u002For concurrent chemotherapy over a period of 6 months.",[234,235,236,29],"Cervical Cancer Screening","Gynecologic Cancers","Treatment Compliance",[238,112,239,240,241,29],"Cervical cancer","Recurrence","Treatment","Compliance","2026-02-03",{"date":244,"type":42},"2026-02-04",{"date":246,"type":42},"2021-02-01",{"date":248,"type":22},"2026-03-31",{"name":250,"class":251},"Tata Memorial Hospital","OTHER_GOV",2,{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":50},"100608744","phase-2-clinical-study-of-thiopegfilgrastim-for-preventing-bone-marrow-suppression-in-thoracic-tumor-chemoradiotherapy-100608744","NCT07205536","Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy","A Clinical Study on the Safety and Efficacy of Mecapegfilgrastim in Preventing Myelosuppression Induced by Concurrent Chemoradiotherapy for Thoracic Malignancies","ANC-IIT-004","Inclusion Criteria:\n\n* Aged 18-75 years at the time of giving informed consent， both sexes eligible\n* Histologically or cytologically confirmed thoracic tumor (esophageal or lung cancer)\n* Investigator judges the patient suitable for treatment with mecapegfilgrastim injection or leucogen tablets\n* Expected survival \\> 3 months\n* Signed informed consent; willing and able to comply with protocol-mandated visits\n* The patient is indicated for concurrent chemoradiotherapy and is currently\u002Freceiving or will receive a high-risk chemotherapy regimen for febrile neutropenia (FN risk ≥20%), or is currently\u002Freceiving or will receive an intermediate-risk chemotherapy regimen for FN (FN risk 10%\\~20%) with additional FN risk factors.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Known hypersensitivity to mecapegfilgrastim, pegylated or non-pegylated rhG-CSF, or any E. coli-derived product\n* Any severe comorbidity that, in the investigator's opinion, compromises patient safety or ability to complete the study\n* Any other condition that, in the investigator's judgment, could interfere with study conduct or interpretation of results",{"count":262,"type":22},30,[25],"This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.",[266,267,29],"Myelosuppression","Thoracic Neoplasms",[269,270],"Neutropenia","Febrile neutropenia","2025-12-10",{"date":273,"type":42},"2025-12-11",{"date":275,"type":42},"2025-08-01",{"date":277,"type":22},"2027-12",{"name":279,"class":49},"Affiliated Hospital of Nantong University",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":4},"100611032","phase-2-ensartinib-after-chemoradiotherapy-in-stage-iii-alk-mutated-nsclc-100611032","NCT07235306","Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC","Ensartinib for the Treatment of Patients With ALK-Mutated Stage III Unresectable NSCLC: A Multicenter, Randomized Controlled, Double-blind Clinical Study","Inclusion Criteria:\n\n* Male or female aged at least 18 years\n* Histologically or cytologically confirmed Stage III unresectable non-small cell lung cancer (NSCLC) with curative treatment intent\n* ALK mutations assessed by FISH, IHC, or NGS\n* ECOG Performance Status of 0 or 1\n* Completion of platinum-based concurrent or sequential chemoradiotherapy as per protocol requirements\n* Chemoradiotherapy must have been completed ≤ 6 weeks prior to randomization\n* No disease progression during or after chemoradiotherapy\n* Life expectancy \\> 12 weeks\n* Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment\n* Signed informed consent form obtained from the patient or their legally authorized representative\n* Male and female patients of childbearing potential agree to use highly effective contraception methods from before entering the trial, throughout the study, and until 8 weeks after discontinuation of study treatment\n\nExclusion Criteria:\n\n* Mixed histology of small cell and non-small cell lung cancer\n* Symptomatic pneumonitis following chemoradiotherapy that has not resolved to ≤ Grade 1 (per CTCAE criteria) prior to randomization;\n* Any unresolved toxicity from prior chemoradiotherapy with toxicity ≥ Grade 2 (according to CTCAE criteria);\n* Poor cardiac function, including but not limited to any of the following:\n\n  * Mean resting corrected QT interval (QTc) \\> 470 msec (obtained from 3 ECGs);\n  * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG;\n  * Any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or concomitant use of any known drugs that prolong the QT interval and may lead to Torsades de Pointes;\n* Inadequate bone marrow reserve or organ function;\n* History of other malignant malignancies, except for adequately treated non-melanoma skin cancer or malignant lentigo, cured carcinoma in situ, or other solid tumors cured \\> 5 years ago with no evidence of disease and considered by the treating physician to have a low risk of recurrence;\n* Severe or uncontrolled systemic diseases: including uncontrolled hypertension and active bleeding tendency; or active infections, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);\n* Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of ensartinib;\n* Any prior chemotherapy, radiotherapy, immunotherapy, or investigational drug therapy beyond the definitive treatment for locally advanced disease;\n* Prior treatment with any ALK tyrosine kinase inhibitor (ALK-TKI);\n* Major surgery within 4 weeks prior to the first dose of study drug;\n* Current use of medications known to be strong inducers of CYP3A4 (which cannot be discontinued at least 3 weeks prior to the first dose of study drug);\n* Known hypersensitivity to ensartinib or any excipient in this product;\n* Pregnant or lactating women;\n* History of definite neurological or psychiatric disorders, including epilepsy or dementia;\n* Any other condition that, in the judgment of the investigator, would make the subject unsuitable for participation in the study.",{"count":288,"type":22},45,[25],"The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, its benefit is limited in patients with driver gene mutations. The LAURA study established a new paradigm of targeted consolidation therapy after CRT for patients with EGFR mutations. Although retrospective data support the efficacy of ALK-TKIs, no randomized controlled trial (RCT) has clearly demonstrated the value of ALK-TKI maintenance therapy after CRT. This study adopts a multicenter, randomized, double-blind, placebo-controlled design aimed at evaluating the efficacy and safety of ensartinib in patients with ALK-positive unresectable stage III NSCLC.",[87,292,29,293],"Ensartinib","ALK","2025-11-17",{"date":296,"type":42},"2025-11-19",{"date":298,"type":22},"2025-12-01",{"date":300,"type":22},"2031-12-31",{"name":302,"class":49},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":50},"100599590","phase-2-surufatinib-in-combination-with-neoadjuvant-chemo-immunotherapy-and-concurrent-chemoradiotherapy-for-patients-with-unresectable-locally-advanced-esophageal-squamous-cell-carcinoma-100599590","NCT07086469","Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","A Prospective, Single-arm, Phase II Clinical Trial of Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC).\n* Locally advanced, unresectable esophageal cancer assessed by endoscopic ultrasound and imaging studies, including esophagography, contrast-enhanced CT scans of the lower neck, chest, and upper abdomen, MRI of the lower neck and chest, whole-body bone scintigraphy, or PET\u002FCT; staged as T2-4, N0-3, M0-1 (M1 limited to supraclavicular lymph node metastasis).\n* Male or female patients aged 18 to 80 years.\n* No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy.\n* Expected life expectancy of at least 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and bone marrow function defined as: Forced expiratory volume in one second (FEV1) ≥ 1000 mL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Creatinine clearance ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.\n* Signed and dated informed consent form must be obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n* Participation in another clinical trial simultaneously, except for observational (non-interventional) studies.\n* Prior use of any targeted therapy.\n* Major surgery within 4 weeks prior to study entry (excluding vascular access procedures).\n* Uncontrolled comorbidities, including but not limited to active or ongoing infections, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, arrhythmias, active peptic ulcer disease or gastritis, intestinal perforation, bowel obstruction, active bleeding disorders, or psychiatric\u002Fsocial conditions that may impair compliance with study requirements or the ability to provide informed consent.\n* Performance status (PS) score of 2-4.\n* Presence of any of the following organ or bone marrow dysfunctions: Forced expiratory volume in one second (FEV1) \\\u003C 1000 mL; Absolute neutrophil count (ANC) \\\u003C 1.5 × 10⁹\u002FL; Platelet count \\\u003C 100 × 10⁹\u002FL; Hemoglobin \\\u003C 90 g\u002FL; Creatinine clearance \\\u003C 50 mL\u002Fmin calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin \\> 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2.5 × ULN.\n* Any condition that may interfere with the assessment of efficacy or safety of surufatinib.","80 Years",{"count":312,"type":22},69,[25],"The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.",[186,208,316,29,317],"Neoadjuvant Immunochemotherapy","Esophageal Squamous Cell Carcinoma",[186,208,316,29,317],"2025-11-13",{"date":294,"type":42},{"date":322,"type":42},"2025-07-20",{"date":324,"type":22},"2029-07-19",{"name":195,"class":49},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":344,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":50},"100608177","phase-2-scrt-followed-by-capox--bev--pd-1-inhibitor-for-tnt-in-larc-100608177","NCT07198165","SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy.\n* Exclusion of patients with BRAF mutations or MSI-H status, as determined by pre-enrollment genetic testing including RAS, BRAF, and MSI analysis. RAS mutation status is permitted regardless.\n* Absence of severe intestinal obstruction symptoms and no evidence of distant metastasis confirmed by imaging examinations such as CT, MRI, or PET\u002FCT.\n* Confirmation as locally advanced rectal cancer by rectal MRI, meeting one or more of the following criteria: T3c-d or T4, N2, EMVI(+), MRF(+), lateral lymph node metastasis; or patients with low-lying rectal cancer (≤5 cm from the anal verge) unsuitable for sphincter-preserving surgery prior to neoadjuvant therapy.\n* Age 18 to 75 years.\n* ECOG Performance Status of 0 to 1, without severe comorbid medical conditions.\n* Adequate organ function:\n\nHematopoietic: Hemoglobin ≥90 g\u002FL, Platelets ≥80 × 10\\^9\u002FL, Absolute Neutrophil Count ≥1.5 × 10\\^9\u002FL.\n\nHepatic: ALT and AST \\\u003C 2.5 × ULN. Renal: Serum Creatinine \\\u003C 1.5 × ULN.\n\n* Provision of signed and dated written informed consent.\n\nExclusion Criteria:\n\n* Patients found to have BRAF mutations or MSI-H status.\n* Patients who have previously received chemotherapy, radiotherapy, immunotherapy, targeted therapy, or surgical resection for colorectal cancer prior to enrollment.\n* History or presence of another malignancy (except for early-stage basal cell carcinoma or carcinoma in situ of the cervix) within the past 3 years, with the disease not under control.\n* Patients who are pregnant (confirmed by serum or urine β-HCG test) or breastfeeding.\n* Patients with severe cardiac, hepatic, renal, neurological, or psychiatric diseases.\n* Patients with active infections.\n* Poor overall health status, with an ECOG performance status ≥2.\n* Patients who have undergone organ transplantation requiring immunosuppressive therapy, or those requiring long-term corticosteroid treatment for autoimmune diseases.\n* Patients with comorbid conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the completion of the study.\n* Known hypersensitivity to any of the study drugs.",{"count":334,"type":22},104,[25],"This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC). The hypothesis is that the addition of immunotherapy (PD-1 inhibitor) can significantly improve the complete response (CR) rate and enhance local control while reducing the incidence of distant metastasis. This study will compare the effects of sequential chemoradiotherapy and targeted therapy with or without immunotherapy following short-course radiotherapy, aiming to explore the optimal regimen for total neoadjuvant therapy.",[63,338,339,340,341,342,143,343,29],"Rectal Adenocarcinoma","Rectal Cancer, Radiotherapy","Rectal Cancer Patients","Immunotherapy","Total Neoadjuvant Therapy","Targeted Therapy",[153,342,341,345,29],"Targeted therapy","2025-09-27",{"date":348,"type":42},"2025-09-30",{"date":350,"type":42},"2025-09-05",{"date":352,"type":22},"2030-12-31",{"name":354,"class":49},"Ruijin Hospital",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":381,"locationsCount":50},"100603065","symptoms-burden-in-lung-cancer-patients-undergoing-definitive-chemoradiotherapy-insights-from-electronic-patient-reported-outcomes-100603065","NCT07131670","Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","ePRO-LC-CRT","Inclusion Criteria:\n\n* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC\n* Age ≥ 18 years\n* Receiving definitive chemoradiotherapy\n* Able and willing to complete electronic questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe comorbidities (heart, liver, kidney)\n* Psychiatric illness or cognitive impairment\n* Prior chest or mediastinal radiotherapy",{"count":364,"type":22},100,"This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.",[367,29,368],"Lung Cancer","Patient-Reported Outcomes (PRO)",[370,371,372,373,367,374],"Symptom Burden","Symptom Clusters","Electronic Patient-Reported Outcomes","MDASI-LC","EQ-5D","2025-08-12",{"date":377,"type":42},"2025-08-20",{"date":379,"type":42},"2024-06-01",{"date":248,"type":22},{"name":382,"class":49},"Qian Chu",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100548467","phase-2-induction-chemoimmunotherapy-combined-with-chemoradiotherapy-in-esophageal-cancer-100548467","NCT06421376","Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer","Efficacy and Safety of Inductive Chemoimmunotherapy Followed by Chemoradiotherapy With or Without Surgery in Locally Advanced Esophageal Squamous Cell Cancer: a Single-arm, Prospective, Phase II Trial","Inclusion Criteria:\n\n* 18-80 years old；\n* Eligible patients were histologically confirmed esophageal squamous cell carcinoma;\n* Eligible patients were proven locally advanced ESCC (cT1-2N1-3M0-1, cT3\u002FT4N0-3M0-1, M1 was limited to supraclavicular lymph node metastasis）diagnosed by computed tomography \\[CT\\] and\u002For endoscopic ultrasonography \\[EUS\\] according to the American Joint Committee on Cancer (AJCC) 8th edition staging system；\n* ECOG PS score: 0\\~1；\n* Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g\u002FL ; absolute neutrophil count (NEUT)≥1.5×109\u002FL; platelets (PLT) ≥100×109\u002FL; white blood cell (WBC)≥3.5×109\u002FL,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;\n\nExclusion Criteria:\n\n* Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* patients who had previously received other treatments\n* At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites\n* Those who already have esophageal perforation or are at high risk of esophageal perforation\n* Patients whose tumors invade close to large blood vessels and are at risk of bleeding in the\n* there are active infections, such as active tuberculosis and hepatitis\n* There are contraindications to immunotherapy.\n* Pregnant or lactating women and women of childbearing age do not take reliable contraceptive measures\n* Combined with serious cardiovascular diseases, such as uncontrolled heart failure, coronary heart disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months; and those combined with other uncontrolled acute and chronic diseases such as hypertension and diabetes.\n* Violation of inclusion and exclusion criteria, or other reasons that the researcher believes cannot continue the study of drug treatment.",{"count":391,"type":22},60,[25],"Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for 30-40% of overall survival at 5 year. In recent years, multimodal treatments have proven to be an appropriate therapeutic approach for locally advanced ESCC. Recently, immunotherapy developed rapidly. The purpose of this study was to observe the efficacy and safety of cardonilizumab combined with chemoradiotherapy in the treatment of locally advanced ESCC.",[181,341,30,29,395],"Surgery","2025-05-24",{"date":398,"type":42},"2025-05-30",{"date":400,"type":42},"2024-05-01",{"date":402,"type":22},"2027-12-31",{"name":404,"class":49},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",3,{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":417,"conditions":418,"keywords":422,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":50},"100580169","application-of-intelligent-care-systems-in-radiation-therapy-enhancing-patient-safety-and-reducing-anxiety-through-system-optimization-and-real-time-blood-data-monitoring-100580169","NCT06833801","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization and Real-Time Blood Data Monitoring","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization, Enhanced Education Strategies, and Real-Time Blood Data Monitoring","ICS-RT","Inclusion Criteria:\n\n* Patients undergoing radiation therapy combined with chemotherapy.\n* Age ≥ 18 years.\n* Ability to understand and comply with the study protocol.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or intellectual disability, affecting their ability to understand or follow study procedures.\n* Patients unwilling to complete study questionnaires.\n* Any mental health condition (e.g., major depressive disorder, severe anxiety disorder) that could interfere with participation.\n* Patients with conditions requiring immediate intervention that would make study participation impractical.",{"count":364,"type":22},[416],"NA","This study aims to evaluate the impact of an intelligent care system on radiation therapy patients, focusing on real-time blood data monitoring, optimized patient education, and internal alert systems. The goal is to enhance patient safety, improve treatment adherence, and reduce anxiety by integrating an alert function into the hospital's existing system.\n\nKey interventions include:\n\nReal-time blood monitoring alerts: Healthcare providers will receive automatic notifications of abnormal blood test results to ensure timely intervention.\n\nOptimized patient education materials: Clearer guidance will help patients proactively communicate blood test needs and manage their health during radiation therapy.\n\nInternal reminders: Visual signs and alerts in treatment areas will reinforce patient awareness and engagement.\n\nThe study will compare patients receiving these interventions with those under standard care, assessing treatment compliance, anxiety levels, and clinical outcomes over a 12-month period.",[419,29,420,421],"Radiation Therapy","Anxiety","Adherence",[419,423,424,425,426,427,428,429,430,431],"Intelligent Care System","Real-Time Blood Data Monitoring","Patient Safety","Oncology Treatment Compliance","Cancer Treatment Anxiety","Clinical Decision Support System","Health Education in Radiation Oncology","Automated Blood Test Alerts","Supportive Care in Cancer Patients","2025-02-18",{"date":434,"type":42},"2025-02-20",{"date":434,"type":22},{"date":437,"type":22},"2025-12-31",{"name":439,"class":49},"Chung Shan Medical University",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":463},"100383869","phase-1-chemoradiotherapy-in-unresectable-esophageal-cancer-100383869","NCT04278287","Chemoradiotherapy in Unresectable Esophageal Cancer","A Phase I\u002FII Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002)","Inclusion Criteria:\n\n* 18\\~75 years\n* Pathologically or cytologically proven unresectable esophageal squamous cell carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TNM staging,M1b limited to clavicular or celiac lymph node metastasis)\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences\n* ECOG PS score: 0\\~1\n* NRS2002 score \\\u003C3\n* Estimated survival time ≥3 months\n* Normal organ and marrow function as defined below:\n\nHemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit\n\n* Informed consent\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer\n* Existing active infection such as active tuberculosis and hepatitis\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\n* History of allergic reactions attributed to paclitaxel, albumin or cisplatin\n* Participation in other clinical trials currently or within 4 weeks of selection\n* Pregnant or lactating females",{"count":448,"type":22},105,[450,25],"PHASE1","This phase I\u002FII clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.",[181,29,453,454],"Albumin-bound Paxlitaxel","Unresectable Malignant Neoplasm","2024-12-10",{"date":457,"type":42},"2024-12-13",{"date":459,"type":42},"2019-10-01",{"date":461,"type":22},"2026-12",{"name":404,"class":49},5,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":471,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":50},"100567394","phase-2-sodium-glycididazole-reduces-the-adverse-reactions-of-concurrent-chemoradiotherapy-100567394","NCT06667622","Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy","Sodium Glycididazole Reduces Chemoradiotherapy-related Adverse Reactions During Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients must have histologically or cytologically confirmed non-small cell lung cancer.\n2. Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.\n3. ECOG PS 0-2\n4. Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n1. History of previous radiotherapy.\n2. The previous immune-related pneumonitis ≥ grade 2.\n3. Local lesions require surgery.\n4. History of another primary malignancy.\n5. History of active primary immunodeficiency.\n6. Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.\n7. For any unmitigated toxicity during pre-study chemoradiotherapy.","70 Years",{"count":473,"type":22},40,[25],"To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.",[29],"2024-10-30",{"date":479,"type":42},"2024-10-31",{"date":481,"type":42},"2024-05-29",{"date":483,"type":22},"2026-07-20",{"name":404,"class":49},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":471,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":50},"100547851","phase-2-sintilimab-after-concurrent-chemoradiotherapy-in-elderly-patients-with-esophageal-squamous-cell-carcinoma-100547851","NCT06413342","Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Randomized, Multi-center Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed squamous cell carcinoma of the esophagus, clinically staged before treatment (8th edition of the UICC\u002FAJCC TNM staging system for esophageal squamous cell carcinoma) as stage II-IVb (cT1N2-3M0-1, cT2-4bN0-3M0-1, M1 limited to supraclavicular lymph node metastasis).\n2. Candidates for curative esophageal cancer surgery who are unable to tolerate surgery or refuse surgery.\n3. Age 70 to 85 years.\n4. ECOG performance status of 0-1.\n5. The minimum technical standard for radiotherapy is intensity-modulated radiotherapy (IMRT). The total dose of radiotherapy is 54Gy ± 10%.\n\n   Note: It is recommended that study centers conduct screening within 14 days after subjects complete synchronous chemoradiotherapy.\n6. Concurrent chemotherapy regimen: Single-agent S-1 70mg\u002Fm2, days 1-14 and 29-42, synchronized with radiotherapy for 14 days or longer.\n7. The last cycle of chemotherapy must end before or concurrently with the last session of radiotherapy. Consolidation chemotherapy after radiotherapy is not allowed, and chemotherapy before chemoradiotherapy is not accepted. Patients who have not progressed after chemoradiotherapy, including complete response (CR), partial response (PR), and stable disease (SD), can be enrolled in this study.\n8. Except for hearing loss, hair loss, and fatigue, all toxicities from previous anti-tumor treatments must have recovered to grade ≤1 (according to the National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events \\[CTCAE\\] v5.0) or baseline level before enrollment.\n9. The first dose of study medication must be administered within 42 days after completion of chemoradiotherapy.\n10. No esophageal perforation or active esophageal bleeding, no significant invasion of the trachea or major blood vessels in the chest. No interstitial pneumonia or history of interstitial pneumonia. FEV1 ≥ 0.8L.\n11. Expected survival ≥ 3 months.\n12. Laboratory criteria:\n\n    1. Serum hemoglobin ≥ 90g\u002FL, platelets ≥ 100 × 10\\^9\u002FL, absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL.\n    2. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 40 mL\u002Fmin.\n    3. Serum bilirubin ≤ 1.5 times ULN, AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN, alkaline phosphatase ≤ 5 times ULN.\n    4. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (patients on stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin with an INR within the expected therapeutic range for anticoagulant therapy can be screened).\n13. Patients must sign formal informed consent forms indicating their understanding that this study complies with hospital policies and ethical requirements.\n\nExclusion Criteria:\n\n* 1\\. Patients who underwent surgical resection for esophageal cancer prior to the start of this trial or have previously received treatment with immune checkpoint inhibitors such as anti-PD-1\u002FPD-L1 or CTLA-4 inhibitors.\n\n  2\\. Patients staged as cT1-3N1-2M0, deemed suitable for surgical resection, and requiring surgery.\n\n  3\\. Experience disease progression after chemoradiotherapy. 4. High risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation.\n\n  5\\. History of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, or other uncontrolled acute pulmonary conditions.\n\n  6\\. Poor nutritional status, with a BMI less than 18.5kg\u002Fm2, or PG-SGA score ≥9. 7. Inability to comprehend trial requirements or likelihood of non-compliance with trial requirements.\n\n  8\\. Presence of hematogenous metastases. 9. Presence of other malignant lesions, excluding curable non-melanoma skin cancer, cervical carcinoma in situ, or malignancies with a cure ≥5 years.\n\n  10\\. Known grade 3 to 4 allergic reactions to any treatment component. 11. Participation in other clinical trials within the past 30 days. 12. Active autoimmune diseases or history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); exceptions include vitiligo or resolved atopic asthma without the need for intervention in adulthood; patients with stable doses of thyroid replacement hormone therapy for autoimmune-mediated hypothyroidism and patients with stable doses of insulin for type I diabetes can be included.\n\n  13\\. History of immunodeficiency, including HIV-positive status, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation.\n\n  14\\. Uncontrolled clinical symptoms or diseases of the heart, such as (1) NYHA class II or higher heart failure (2) Unstable angina (3) Myocardial infarction within the past year (4) Clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.\n\n  15\\. Active pulmonary tuberculosis infection detected by history or CT examination, or history of active pulmonary tuberculosis infection within the past year before enrollment, or history of active pulmonary tuberculosis infection more than 1 year ago without proper treatment.\n\n  16\\. Presence of active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 1× 104 copies\u002FmL), hepatitis C (positive HCV antibodies, and HCV-RNA higher than the detection limit of the assay).\n\n  17\\. According to the investigator's judgment, concurrent diseases that pose a serious risk to patient safety or may interfere with patient completion of the study, or other reasons deemed unsuitable for enrollment by the investigator.","85 Years",{"count":494,"type":22},191,[25],"This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress after concurrent chemoradiotherapy.\n\nPatients aged 70-85 years with esophageal squamous cell carcinoma who did not progress after concurrent chemoradiotherapy and meet the inclusion criteria will be stratified according to MRD status (positive vs negative) and randomized in a 1:1 ratio into two groups: the treatment group receiving sintilimab (for patients with a weight \\\u003C60 kg: 3 mg\u002Fkg IV on Day 1 every 3 weeks; for patients with a weight ≥60 kg: 200 mg IV on Day 1 every 3 weeks) and the observation group receiving regular follow-up. Patients should receive the first dose within 42 days after completing the last radiotherapy session and continue treatment until disease progression, intolerable toxicity, loss to follow-up, death, or other circumstances where the investigator determines treatment should be discontinued, whichever occurs first. The maximum duration of sintilimab treatment is 12 months (from the start of treatment), while the observation group will be followed up every 3 months for at least one year. No other anti-tumor treatments are allowed during the study period. The study aims to compare the effects of the two treatment modalities on progression-free survival, overall survival, tumor response, toxicity reactions, and quality of life in elderly patients with esophageal cancer.",[181,29,498,341,499],"Sintilimab","Elderly Patients","2024-07-12",{"date":502,"type":42},"2024-07-16",{"date":379,"type":42},{"date":505,"type":22},"2028-06-01",{"name":507,"class":49},"Zhejiang Cancer Hospital",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":50},"100549117","phase-2-nimotuzumab-concurrent-with-chemoradiotherapy-for-esophageal-cancer-patients-100549117","NCT06429839","Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients","Nimotuzumab Concurrent With Chemoradiotherapy for Elderly or Malnourished Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study","Inclusion Criteria:\n\n* Histologically confirmed esophageal squamous cell carcinoma.\n* No previous treatment for the esophageal carcinoma.\n* KPS score ≥70.\n* NRS-2002 score≥2.\n* Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g\u002FL ; absolute neutrophil count (NEUT)≥1.5×109\u002FL; platelets (PLT) ≥100×109\u002FL; white blood cell (WBC)≥3.5×109\u002FL,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;\n\nExclusion Criteria:\n\n* Previous treatment of the esophageal cancer with surgery, radiation, or chemotherapy.\n* Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites\n* There are active infections, such as active tuberculosis and hepatitis\n* There are contraindications to targeted therapy.",{"count":516,"type":22},55,[25],"Elderly or malnourished patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc.\n\nNimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies.\n\nThe current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab with a dose of 800mg per week and S-1 and concurrent radiotherapy for patients who are elderly or malnourished.",[181,520,29,146,341],"Nimotuzumab","2024-05-21",{"date":523,"type":42},"2024-05-28",{"date":525,"type":42},"2023-03-01",{"date":527,"type":22},"2026-12-31",{"name":404,"class":49},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":546,"locationsCount":50},"100547644","phase-2-nimotuzumab-concurrent-with-chemoradiotherapy-for-patients-with-unresectable-esophageal-squamous-cell-carcinoma-100547644","NCT06410651","Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma","Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma After Failure of Chemotherapy：A Phase II Study","Inclusion Criteria:\n\n* Histologically confirmed esophageal squamous cell carcinoma. Tumor response was evaluated as stable or locoregionally progresive disease or assessed by surgeons being unresectable (without distant metastasis) after induction chemo(immuno)therapy.\n* Cycles of induction chemo(immuno)therapy was 2-4.\n* KPS score ≥70.\n* Main organs and bone marrow function are normal: routine blood tests: hemoglobin (Hb) ≥100g\u002FL ; absolute neutrophil count (NEUT)≥1.5×109\u002FL; platelets (PLT) ≥100×109\u002FL; white blood cell (WBC)≥3.5×109\u002FL,biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×UNL; serum total bilirubin (TBIL) ≤1.5×UNL; serum creatinine ( Cr) 1.0×1.5UNL, and BUN≤1.0×UNL;\n\nExclusion Criteria:\n\n* Those combined with other primary malignant tumors other than esophageal cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* At the time of diagnosis, there were distant and hematogenous metastases beyond the supraclavicular lymph node region, including retroperitoneal multiple lymph node metastasis, bone metastasis, brain metastasis, lung metastasis, liver metastasis, malignant pleural effusion and ascites\n* There are active infections, such as active tuberculosis and hepatitis\n* There are contraindications to targeted therapy.",{"count":537,"type":22},53,[25],"Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc.\n\nNimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies.\n\nThe current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemo(immuno)therapy.",[181,520,29,146,341],"2024-05-10",{"date":543,"type":42},"2024-05-13",{"date":525,"type":42},{"date":527,"type":22},{"name":404,"class":49},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":228,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":50},"100535776","toripalimab-combined-with-definitive-ccrt-for-lacc-patients-100535776","NCT06256224","Toripalimab Combined With Definitive CCRT for LACC Patients","Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients","Inclusion Criteria:\n\n* more than 18 years old females\n* had newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix\n* FIGO 2018 stage IB3 to IVA with no evidence of distant metastasis\n* ECOG PS 0-1 without major organ failure\n* signed informed consent voluntarily\n\nExclusion Criteria:\n\n* previously suffered from immunodeficiency disorders\n* had any condition that researchers believed to be associated with increased risk of treatment\n* Previously received or currently receiving other PD-1 antibody treatments or other immunotherapies targeting PD-1\u002FPD-L1",{"count":555,"type":22},150,[416],"Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent\u002Fmetastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, showed promising anti-tumor efficacy in multiple solid tumors. This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC.",[559,29,341],"Cervical Cancer","2024-04-22",{"date":562,"type":42},"2024-04-24",{"date":564,"type":42},"2024-02-02",{"date":566,"type":22},"2028-12-31",{"name":354,"class":49},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":574,"sex":17,"minAge":18,"maxAge":492,"enrollmentInfo":575,"targetDuration":577,"studyType":60,"phases":4,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":50},"100530750","oral-microbiome-is-associated-with-the-response-to-chemoradiotherapy-in-initial-inoperable-patients-with-esophageal-squamous-cell-cancer-100530750","NCT06190847","Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer","Inclusion Criteria:\n\n* 18-85 years old;\n\n  * Eastern Cooperative Oncology Group (ECOG) 0-2;\n  * Esophageal squamous cell carcinoma;\n  * cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n  * initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n  * Treatment naive;\n  * No contraindications for adjuvant chemoradiotherapy;\n  * Signature of inform consent.\n\nExclusion Criteria:\n\n* • younger than 18 years old or older than 85 years old;\n\n  * ECOG\\>2;\n  * Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n  * cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n  * Resectable at initial diagnosis confirmed by thoracic surgeons;\n  * Previous treatment of chemotherapy, radiotherapy, and other treatment;\n  * Contraindications for chemoradiotherapy;\n  * No signature of inform consent.",true,{"count":576,"type":22},97,"24 Months","Esophageal cancer accounts for more than half of the world, seriously affecting people's health in China. 95% patients are squamous cell carcinoma. Surgery is the preferred treatment for early and middle stage esophageal cancer, but patients with clinical stage T4b or other surgical contraindications have no surgical opportunity. In recent years, radical chemoradiotherapy has played a key role in the treatment of local advanced esophageal cancer with some poor predicting biomarkers. Oral bacteria may play a pathogenic role in cancer and other chronic diseases by producing chemical carcinogens and inflammatory factors through direct metabolism. A large number of studies have also suggested that tooth loss and poor oral hygiene are closely related to upper digestive tract cancer, indicating the possible role of oral microorganisms in the occurrence and development of upper digestive tract cancer, and saliva is the main source of oral flora colonization. Therefore, it is worth further research to explore the interaction between microbial metabolism imbalance and radiotherapy in patients with esophageal cancer. In summary, we intend to conduct a prospective cohort study to explore the role of salivary microbes in radiotherapy in patients with initially inoperable patients with local advanced esophageal cancer.",[317,29,580],"Initial Inoperable","2023-12-20",{"date":583,"type":42},"2024-01-05",{"date":585,"type":42},"2023-07-01",{"date":587,"type":22},"2026-07-01",{"name":589,"class":251},"Anhui Provincial Hospital",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":492,"enrollmentInfo":597,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":606,"leadSponsor":608,"locationsCount":50},"100503310","whole-course-immunonutrition-combined-with-chemoradiotherapyicis-for-local-advanced-patients-with-inoperable-esophageal-squamous-cell-carcinoma-100503310","NCT05833594","Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","Anhui Provincial Hospita","Inclusion Criteria:\n\n* 18-85 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-2;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n* initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 85 years old;\n* ECOG\\>2;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n* Resectable at initial diagnosis confirmed by thoracic surgeons;\n* Previous treatment of chemotherapy, radiotherapy, and other treatment;\n* Contraindications for chemoradiotherapy;\n* No signature of inform consent.",{"count":598,"type":22},70,"Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.",[317,29,601,602],"Immunonutrition","Inoperable",{"date":604,"type":42},"2023-12-26",{"date":585,"type":42},{"date":607,"type":22},"2026-12-01",{"name":589,"class":251},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":228,"minAge":18,"maxAge":19,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":50},"100495741","phase-3-concurrent-chemoradiotherapy-combined-with-adjuvant-chemotherapy-treated-advanced-cervical-cancer-100495741","NCT05735145","Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer","A Prospective Randomized Controlled Trial for Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy in the Treatment of Advanced Cervical Cancer at 2018 FIGO Staging","Inclusion Criteria:\n\n* Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma\n* FIGO stage IB3, IIA2, IIB-IVA patients in 2018\n* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment\n* Aged 18-75 years\n* PS score 0-1\n* Serum hemoglobin \\>=100\\*10\\^9\u002FL, blood platelet \\>= 100000\u002FμL, absolute count of neutrophils\\>=1500\u002FμL; 7.Serum creatinine \\\u003C=1.5 UNL or creatinine clearance \\>= 60 ml\u002Fmin; 8.Serum bilirubin \\\u003C=1.5 UNL, AST (SGOT) and ALT (SGPT)\\\u003C= 1.5 UNL\n* Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \\> 6 months.\n\nExclusion Criteria:\n\n* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment\n* Patients who have received neoadjuvant chemotherapy and surgery\n* Patients with cognitive impairment\n* Patients with any distant metastases\n* Patients with any other malignancy within 5 years\n* Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception\n* Severe bone marrow dysfunction\n* Patients with bleeding tendency\n* Drug abusers or alcohol addicts\n* Those who are known to have a third or fourth degree allergic reaction to any treatment in the study",{"count":617,"type":22},108,[140],"This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.",[621,29,622],"Uterine Cervical Neoplasms","Adjuvant Chemotherapy","2023-02-16",{"date":625,"type":42},"2023-02-21",{"date":627,"type":42},"2022-07-01",{"date":629,"type":22},"2027-06-30",{"name":631,"class":49},"Fourth Affiliated Hospital of Guangxi Medical University",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":471,"enrollmentInfo":639,"targetDuration":4,"studyType":23,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":50},"100449230","chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm-100449230","NCT05129774","Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM","Concurrent Chemoradiotherapy Sequenced Radical Surgery for Para-aortic Lymph Node Metastasis of Left-sided Colon and Rectal Cancer","Inclusion Criteria:\n\n* age at enrollment is ≥ 18 and ≤ 75 years\n* ECOG PS 0-1\n* histologically confirmed left-sided colon and rectal carcinoma\n* synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery\n* patients potential to receive surgery and achieve no evidence of disease (NED)\n* able to tolerate surgery\n* providing written informed consent\n\nExclusion Criteria:\n\n* local invasion or distant metastasis other than para-aoritc lymph nodes\n* history of other malignant tumor\n* coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)\n* emergency surgery",{"count":473,"type":22},[416],"In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been no standard treatment strategy for this situation. The present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis",[643,644,29],"Colorectal Neoplasms Malignant","Lymph Node Excision","2021-11-18",{"date":647,"type":42},"2021-11-22",{"date":649,"type":22},"2022-01-01",{"date":651,"type":22},"2027-01-01",{"name":653,"class":49},"Qilu Hospital of Shandong University"]